At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,879 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Semaglutide for Type 2 Diabetes. Completed, enrolled 1,879 participants across 127 sites in 9 countries.
Detailed Summary
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesArgentina, Australia, Brazil, Canada, Israel, Mexico, Puerto Rico, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartJul 2019
Primary CompletionJan 2021
Study CompletionFeb 2021
TodayJul 2026
First PostedJun 17, 2019
Enrollment StartJul 30, 2019
Primary CompletionJan 28, 2021
Study CompletionFeb 15, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.0 years ago
Interventions
Tirzepatidedrug
Administered SC
Semaglutidedrug
Administered SC